The global ceftaroline fosamil market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The ceftaroline fosamil market is driven by factors such as increasing prevalence of drug-resistant bacteria and increasing number of hospital acquired infections. The ceftaroline fosamil market is segmented on the basis of type, application and region. On the basis of type, the ceftaroline fosamil market is segmented into injection type and oral type. On the basis of application, it is segmented into druresistant staphylococcus aureus infection and GraNegative bacterial infection. Geographically, it has been analyzed across North America, Latin America, Europe, Asia Pacific and Middle East & Africa regions.
North America accounted for more than one-third share in 2017 owing to high prevalence rates for drug-resistant bacteria in this region coupled with high healthcare expenditure per capita in this region which drives demand for new drugs such as ceftaroline fosamil which are expensive but offer better efficacy against drug resistant bacteria compared to other antibiotics available in this region such as vancomycin or linezolid which are cheaper but have lower efficacy against drug resistant bacteria due to their low potency against these pathogens; hence driving demand for new drugs like ceftaroline fosamil that offer better efficacy against these pathogens at higher prices than other antibiotics available in this region like vancomycin or linezolid that have lower efficacy against these pathogens due to their low potency against these pathogens; hence driving demand for new drugs like ceftaroline fosamil that offer better efficacy against these pathogens at higher prices than other antibiotics available in this region like vancomycin or linezolid that have lower efficacy against these pathogens due to their low potency against these pathogeneses.
Ceftaroline Fosamil is a cephalosporin antibiotic that is used to treat bacterial infections. Ceftaroline Fosamil has been approved for use in adults and children over the age of 2 years.
Industry Growth Insights published a new data on “Ceftaroline Fosamil Market”. The research report is titled “Ceftaroline Fosamil Market research by Types (Injection Type, Oral Type), By Applications (Drug-resistant staphylococcus aureus infection, Gram-Negative Bacterial Infection, Others), By Players/Companies Roche, Pfizer, Abbvie, Johnson, Sanofi, Merck, Novartis, Gilead, GSK, Amgen, Hayao”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Ceftaroline Fosamil Market Research Report
By Type
Injection Type, Oral Type
By Application
Drug-resistant staphylococcus aureus infection, Gram-Negative Bacterial Infection, Others
By Companies
Roche, Pfizer, Abbvie, Johnson, Sanofi, Merck, Novartis, Gilead, GSK, Amgen, Hayao
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Ceftaroline Fosamil Market Report Segments:
The global Ceftaroline Fosamil market is segmented on the basis of:
Types
Injection Type, Oral Type
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Drug-resistant staphylococcus aureus infection, Gram-Negative Bacterial Infection, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Pfizer
- Abbvie
- Johnson
- Sanofi
- Merck
- Novartis
- Gilead
- GSK
- Amgen
- Hayao
Highlights of The Ceftaroline Fosamil Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection Type
- Oral Type
- By Application:
- Drug-resistant staphylococcus aureus infection
- Gram-Negative Bacterial Infection
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ceftaroline Fosamil Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ceftaroline fosamil is a medication used to treat respiratory infections. It works by killing the bacteria that is causing the infection.
Some of the major players in the ceftaroline fosamil market are Roche, Pfizer, Abbvie, Johnson, Sanofi, Merck, Novartis, Gilead, GSK, Amgen, Hayao.
The ceftaroline fosamil market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ceftaroline Fosamil Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Ceftaroline Fosamil Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Ceftaroline Fosamil Market - Supply Chain
4.5. Global Ceftaroline Fosamil Market Forecast
4.5.1. Ceftaroline Fosamil Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Ceftaroline Fosamil Market Size (000 Units) and Y-o-Y Growth
4.5.3. Ceftaroline Fosamil Market Absolute $ Opportunity
5. Global Ceftaroline Fosamil Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Ceftaroline Fosamil Market Size and Volume Forecast by Type
5.3.1. Injection Type
5.3.2. Oral Type
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Ceftaroline Fosamil Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Ceftaroline Fosamil Market Size and Volume Forecast by Application
6.3.1. Drug-resistant staphylococcus aureus infection
6.3.2. Gram-Negative Bacterial Infection
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Ceftaroline Fosamil Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Ceftaroline Fosamil Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Ceftaroline Fosamil Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Ceftaroline Fosamil Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Ceftaroline Fosamil Demand Share Forecast, 2019-2026
9. North America Ceftaroline Fosamil Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Ceftaroline Fosamil Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Ceftaroline Fosamil Market Size and Volume Forecast by Application
9.4.1. Drug-resistant staphylococcus aureus infection
9.4.2. Gram-Negative Bacterial Infection
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Ceftaroline Fosamil Market Size and Volume Forecast by Type
9.7.1. Injection Type
9.7.2. Oral Type
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Ceftaroline Fosamil Demand Share Forecast, 2019-2026
10. Latin America Ceftaroline Fosamil Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Ceftaroline Fosamil Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Ceftaroline Fosamil Market Size and Volume Forecast by Application
10.4.1. Drug-resistant staphylococcus aureus infection
10.4.2. Gram-Negative Bacterial Infection
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Ceftaroline Fosamil Market Size and Volume Forecast by Type
10.7.1. Injection Type
10.7.2. Oral Type
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Ceftaroline Fosamil Demand Share Forecast, 2019-2026
11. Europe Ceftaroline Fosamil Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Ceftaroline Fosamil Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Ceftaroline Fosamil Market Size and Volume Forecast by Application
11.4.1. Drug-resistant staphylococcus aureus infection
11.4.2. Gram-Negative Bacterial Infection
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Ceftaroline Fosamil Market Size and Volume Forecast by Type
11.7.1. Injection Type
11.7.2. Oral Type
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Ceftaroline Fosamil Demand Share, 2019-2026
12. Asia Pacific Ceftaroline Fosamil Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Ceftaroline Fosamil Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Ceftaroline Fosamil Market Size and Volume Forecast by Application
12.4.1. Drug-resistant staphylococcus aureus infection
12.4.2. Gram-Negative Bacterial Infection
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Ceftaroline Fosamil Market Size and Volume Forecast by Type
12.7.1. Injection Type
12.7.2. Oral Type
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Ceftaroline Fosamil Demand Share, 2019-2026
13. Middle East & Africa Ceftaroline Fosamil Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Ceftaroline Fosamil Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Ceftaroline Fosamil Market Size and Volume Forecast by Application
13.4.1. Drug-resistant staphylococcus aureus infection
13.4.2. Gram-Negative Bacterial Infection
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Ceftaroline Fosamil Market Size and Volume Forecast by Type
13.7.1. Injection Type
13.7.2. Oral Type
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Ceftaroline Fosamil Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Ceftaroline Fosamil Market: Market Share Analysis
14.2. Ceftaroline Fosamil Distributors and Customers
14.3. Ceftaroline Fosamil Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Abbvie
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Merck
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novartis
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Gilead
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. GSK
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Amgen
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Hayao
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
